Inmune Bio (INMB) Interest & Investment Income (2019 - 2020)
Inmune Bio (INMB) posted Interest & Investment Income of $21854.0 for Q1 2020, up 55.15% sequentially from $14086.0 in Q4 2019, and up 117.63% YoY from $10042.0 in Q2 2019.
Inmune Bio (INMB) Interest & Investment Income (2019 - 2020) Analysis & Trends
Inmune Bio has reported Interest & Investment Income for 2 years, with the latest figure at $21854.0 in Q1 2020.
- Quarterly Interest & Investment Income rose 117.63% year-over-year to $21854.0 in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $89500.0 (changed N/A YoY) and the FY2019 annual result came in at $77688.0, changed N/A from the prior year.
- Interest & Investment Income rose to $21854.0 in Q1 2020 per INMB's latest filing, from $14086.0 in the prior quarter.
- Over five years, Interest & Investment Income peaked at $36340.0 in Q2 2019 and troughed at $10042.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 21,854.00 |
| Dec 31, 2019 | 14,086.00 |
| Sep 30, 2019 | 17,220.00 |
| Jun 30, 2019 | 36,340.00 |
| Mar 31, 2019 | 10,042.00 |